Source: European Medicines Agency (EU) Revision Year: 2019 Publisher: Glaxo Group Ltd, 980 Great West Road, Brentford, Middlesex, TW8 9GS, United Kingdom
Altargo 10 mg/g ointment.
| Pharmaceutical Form |
|---|
|
Ointment. Smooth, off-white ointment. |
Each gram of ointment contains 10 mg retapamulin (1% w/w).
Excipient(s) with known effect: Each gram of ointment contains up to 20 micrograms of butylated hydroxytoluene (E321).
For the full list of excipients, see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Retapamulin |
Retapamulin is a semi-synthetic derivative of the compound pleuromutilin, which is isolated through fermentation from Clitopilus passeckerianus. Retapamulin selectively inhibits bacterial protein synthesis by interacting at a unique site on the 50S subunit of the bacterial ribosome that is distinct from the binding sites of other non-pleuromutilin antibacterial agents that interact with the ribosome. |
| List of Excipients |
|---|
|
White soft paraffin |
0.5 g aluminium foil sachet. Carton of 12 sachets.
5 g, 10 g and 15 g aluminium tubes with a plastic screw cap. Carton of 1 tube.
Not all pack sizes may be marketed.
Glaxo Group Ltd, 980 Great West Road, Brentford, Middlesex, TW8 9GS, United Kingdom
EU/1/07/390/001
EU/1/07/390/002
EU/1/07/390/003
EU/1/07/390/004
Date of first authorisation: 24 May 2007
Date of latest renewal: 20 April 2012
| Drug | Countries | |
|---|---|---|
| ALTARGO | Brazil, Estonia, Lithuania |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
